These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 3875671)

  • 1. Inhibitors of plasma thromboplastin antecedent (factor XI): studies on mechanism of inhibition.
    Goldsmith GH; Silverman P
    J Lab Clin Med; 1985 Sep; 106(3):279-85. PubMed ID: 3875671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Partial purification of plasma thromboplastin antecedent (factor XI) and its activation by trypsin.
    Saito H; Ratnoff OD; Marshall JS; Pensky J
    J Clin Invest; 1973 Apr; 52(4):850-61. PubMed ID: 4266422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Studies on plasma thromboplastin antecedent (factor XI), PTA deficiency and inhibition of PTA by plasma: pharmacologic inhibitors and specific antiserum.
    Forbes CD; Ratnoff OD
    J Lab Clin Med; 1972 Jan; 79(1):113-27. PubMed ID: 4257309
    [No Abstract]   [Full Text] [Related]  

  • 4. A unique precipitating autoantibody against plasma thromboplastin antecedent associated with multiple apparent plasma clotting factor deficiencies in a patient with systemic lupus erythematosus.
    Poon MC; Saito H; Koopman WJ
    Blood; 1984 Jun; 63(6):1309-17. PubMed ID: 6426550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of prekallikrein and high-molecular-weight kininogen in the contact activation of Hageman factor (factor XII) by sulfatides and other agents.
    España F; Ratnoff OD
    J Lab Clin Med; 1983 Oct; 102(4):487-99. PubMed ID: 6604770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of heparin on the activation of factor XI by fibrin-bound thrombin.
    von dem Borne PA; Meijers JC; Bouma BN
    Thromb Haemost; 1996 Sep; 76(3):347-53. PubMed ID: 8883269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma thromboplastin antecedent (PTA, factor XI): a specific and sensitive radioimmunoassay.
    Saito H; Goldsmith GH
    Blood; 1977 Sep; 50(3):377-85. PubMed ID: 884316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Studies on a circulating anticoagulant inhibiting factor XI in a patient with congenital deficiency and carcinoma of the prostate.
    Chediak J; Madej-Zevin P; Ratnoff OD; Goldsmith GH; Everson B
    Br J Haematol; 1986 May; 63(1):123-33. PubMed ID: 3486671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acquired factor XI inhibitors in two patients with hereditary factor XI deficiency.
    Morgan K; Schiffman S; Feinstein D
    Thromb Haemost; 1984 Jul; 51(3):371-5. PubMed ID: 6333735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A simple and accurate microplate assay for the determination of factor XI in plasma.
    Scott CF; Colman RW
    J Lab Clin Med; 1988 Jun; 111(6):708-14. PubMed ID: 3373114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surface adsorption of factor XI. II. Evidence that different mechanisms are involved in binding to glass and plastic materials.
    Mannhalter C; Schiffman S
    Thromb Haemost; 1982 Jun; 47(3):214-7. PubMed ID: 6981227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hemostatic defect due to acquired circulating inhibitors against lipid procoagulant and factor VIII.
    Pechet L; Snyder LM; Chesney C; Colman RW
    Thromb Diath Haemorrh; 1974 Sep; 32(1):90-104. PubMed ID: 4548947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Studies on a circulating anticoagulant in systemic lupus erythematosus: evidence for inhibition of the function of activated plasma thromboplastin antecedent (factor XIa).
    Krieger H; Leddy JP; Breckenridge RT
    Blood; 1975 Aug; 46(2):189-97. PubMed ID: 237589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis, and biological evaluation of peptidomimetic inhibitors of factor XIa as novel anticoagulants.
    Lin J; Deng H; Jin L; Pandey P; Quinn J; Cantin S; Rynkiewicz MJ; Gorga JC; Bibbins F; Celatka CA; Nagafuji P; Bannister TD; Meyers HV; Babine RE; Hayward NJ; Weaver D; Benjamin H; Stassen F; Abdel-Meguid SS; Strickler JE
    J Med Chem; 2006 Dec; 49(26):7781-91. PubMed ID: 17181160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contact-activated fibrinolysis: role of surface concentration and high-molecular-weight kininogen.
    Goldsmith GH
    J Lab Clin Med; 1980 Aug; 96(2):222-31. PubMed ID: 7400661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The inhibitory properties of plasma against activated plasma thromboplastin antecedent (factor XIa) in hereditary angioneurotic edema.
    Ratnoff OD; Pensky J; Donaldson VH; Amir J
    J Lab Clin Med; 1972 Dec; 80(6):803-9. PubMed ID: 4634502
    [No Abstract]   [Full Text] [Related]  

  • 17. In vitro anticoagulation monitoring of low-molecular-weight heparin.
    Wang JQ; Shi XB; Yang JG; Hu DY
    Chin Med J (Engl); 2009 May; 122(10):1199-202. PubMed ID: 19493471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Different anticoagulant and immunological properties of anti-prothrombin antibodies in patients with antiphospholipid antibodies.
    Galli M; Beretta G; Daldossi M; Bevers EM; Barbui T
    Thromb Haemost; 1997 Mar; 77(3):486-91. PubMed ID: 9065999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Studies on the product of the reaction between activated Hageman factor (factor XII) and plasma thromboplastin antecedent (factor XI).
    Ratnoff OD
    J Lab Clin Med; 1972 Nov; 80(5):704-10. PubMed ID: 4673237
    [No Abstract]   [Full Text] [Related]  

  • 20. Plasma inhibition of activated plasma thromboplastin antecedent (factor XIa) in pregnancy.
    Amir J; Pensky J; Ratnoff OD
    J Lab Clin Med; 1972 Jan; 79(1):106-12. PubMed ID: 4109114
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.